Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial
Thierry Conroy(Inserm), Christophe Borg(Centre Hospitalier Universitaire de Besançon), E. Rio(Institut de Cancérologie de l'Ouest), Clotilde Morand(Roche (France)), D. Gargot, V. Vendrely(Centre Hospitalier Universitaire de Bordeaux), Valérie Boige(Inserm), Nathalie Mesgouez‐Nebout(Institut de Cancérologie de l'Ouest), Ludovic Evesque(Centre Antoine Lacassagne), Sophie Gourgou(Université de Montpellier), Xavier Artignan(Centre Hospitalier privé Saint Grégoire), Nathalie Bonichon-Lamichhane, Pierre-Luc Etienne, Christelle de la Fouchardière(Aix-Marseille Université), Alice Boilève(Institut Gustave Roussy), Olivier Bouché(CHU Dijon Bourgogne), Matthieu Delaye(Institut Gustave Roussy), Florence Castan(Université de Montpellier), Veronica Pezzella(UniCancer Group), Christophe Louvet(Institute Mutualiste Montsouris)
Cited by 187
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k